15 research outputs found
Alpha-tocopherol affects gene expression patterns of rabbit cumulus complexes and reduces apoptosis rate during in vitro maturation
Oxidative stress compromises oocyte developmental competence during in vitro maturation (IVM). Antioxidants
such as vitamin E may avoid this imbalance. The aim of this study was to investigate the effect of a-Tocopherol
(α-TocOH) on the relative mRNA abundance of genes involved in cumulus expansion (GJA1, PTGS2), cell cycle
and viability (AKT1), cell cycle regulation and apoptosis (Tp53, CASP3) and antioxidant response (SOD2, GPX1,
CAT) in rabbit cumulus oocyte complexes (COCs) in vitro matured. The apoptosis index in cumulus cells (CCs) and
the hydrogen peroxide (H2O2) released by the COCs in maturation media were also assessed. For these purposes,
COCs from follicles ≥1mm were recovered, selected and in vitro-matured for 16h (38ºC, 5% CO2) in a medium
containing TCM-199 (Sigma, Madrid, Spain) with 0.3% bovine serum albumin (Sigma, Madrid, Spain) and 10
ng/mL Epidermal Growth Factor (EGF) (Sigma, Madrid, Spain) supplemented with 0, 100, 200 or 400 μM α-
TocOH (Sigma, Madrid, Spain), named as 0E, 100E, 200E and 400E groups, respectivel
Remote control of apomorphine infusion rate in Parkinson's disease: Real-time dose variations according to the patients' motor state. A proof of concept.
Postprint (author's final draft
Genomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans
We present the distribution of CYP2D6, CYP2C9, and CYP2C19 variants and predicted phenotypes in 33 native and
admixed populations from Ibero-America (n > 6,000) in the context of genetic ancestry (n = 3,387). Continental
ancestries are the major determinants of frequencies of the increased-activity allele CYP2C19*17 and CYP2C19
gUMs (negatively associated with Native American ancestry), decreased-activity alleles CYP2D6*41 and CYP2C9*2
(positively associated with European ancestry), and decreased-activity alleles CYP2D6*17 and CYP2D6*29 (positively
associated with African ancestry). For the rare alleles, CYP2C9*2 and CYPC19*17, European admixture accounts
for their presence in Native American populations, but rare alleles CYP2D6*5 (null-activity), CYP2D6-multiplication
alleles (increased activity), and CYP2C9*3 (decreased-activity) were present in the pre-Columbian Americas.
The study of a broad spectrum of Native American populations from different ethno-linguistic groups show how
autochthonous diversity shaped the distribution of pharmaco-alleles and give insights on the prevalence of clinically
relevant phenotypes associated with drugs, such as paroxetine, tamoxifen, warfarin, and clopidogrel
a-Tocopherol modifies the expression of genes related to oxidative stress and apoptosis during in vitro maturation and enhances the developmental competence of rabbit oocytes
The developmental competence of in vitro maturation (IVM) oocytes can be enhanced by antioxidant agents. The present study investigated, for the first time in the rabbit model, the effect of adding a-tocopherol (0, 100, 200 and 400 mM) during IVM on putative transcripts involved in antioxidant defence (superoxide dismutase 2, mitochondrial (SOD2), glutathione peroxidase 1 (GPX1), catalase (CAT)), cell cycle regulation and apoptosis cascade (apoptosistumour protein 53 (TP53), caspase 3, apoptosis-related cysteine protease (CASP3)), cell cycle progression (cellular cycle V-Akt murine thymoma viral oncogene homologue 1 (AKT1)), cumulus expansion (gap junction protein, alpha 1, 43 kDa (GJA1) and prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclo-oxygenase) (PTGS2)) and metabolism (glucose-6-phosphate dehydrogenase (G6PD)). Meiotic progression, mitochondrial reallocation, cumulus cell apoptosis and the developmental competence of oocytes after IVF were also assessed. Expression of SOD2, CAT, TP53, CASP3 and GJA1 was downregulated in cumulus–oocyte complexes (COCs) after IVM with 100 mM a-tocopherol compared with the group without the antioxidant. The apoptotic rate and the percentage of a non-migrated mitochondrial pattern were lower in COCs cultured with 100 mM a-tocopherol, consistent with better-quality oocytes. In fact, early embryo development was improved when 100 mM a-tocopherol was included in the IVM medium, but remained low compared with in vivomatured oocytes. In conclusion, the addition of 100 mM a-tocopherol to the maturation medium is a suitable approach to manage oxidative stress and apoptosis, as well as for increasing the in vitro developmental competence of rabbit oocytes
Improvements in the conception rate, milk composition and embryo quality of rabbit does after dietary enrichment with n-3 polyunsaturated fatty acids
This work attempts to confirm the effect of an enriched diet with n-3 polyunsaturated fatty acids (PUFA) trying to mitigate the reproductive performances issues such as low conception rate of primiparous rabbits. A total of 127 does were fed ad libitum throughout their two first cycles with two diets with different fat sources: mixed fat in the control and salmon oil in the enriched one, with 3.19 g/100 g (n=63 does) and 28.77 g/100 g (n=64 does) of n-3 of the total fatty acid, respectively. Feed intake was similar between groups ( P>0.05). Plasma progesterone concentration was higher in the enriched females than in control ones at 7 (30.9 ± 2.18 v. 23.9 ± 2.30 ng/ml, respectively; P= 0.029) and 14 (38.7 ± 2.18 v. 28.2 ± 2.30 ng/ml, respectively; P=0.001) days of first gestation. Considering both cycles, reproductive parameters of mothers (fertility, duration of gestation and prolificacy) and litter parameters (weight at parturition and weaning, mortality and average daily gain (ADG) of kits during lactation) were similar in both groups. However, individual measurements of neonates of enriched group improved 5.87%, 7.10% and 18.01% ( P 0.05), but embryo apoptosis rate was higher in control group than in enriched one (31.1 ± 4.56% v. 17.1 ± 3.87%, respectively; P < 0.05). In conclusion, dietary PUFA enrichment from the rearing and throughout two productive cycles improved plasma progesterone during pregnancy, fertility, milk fatty acid profile and neonates development of primiparous supporting the beneficial effect of n-3 PUFA supplementation in rabbit does
KIR2DL2/S2 and KIR2DS5 in alcoholic cirrhotic patients undergoing liver transplantation
Introduction: The molecular mechanisms underlying alcoholic liver fibrosis
and cirrhosis are not completely understood. Hepatic fibrosis involves the
interplay of diverse cells and factors, including hepatic stellate cells (HSCs),
Kupffer, NK cells, and T-lymphocyte subsets. Killer-cell immunoglobulin-like
receptors (KIR) are membrane receptors involved in mediation between NK
and activated HSCs, regulating NK cell function through their interaction
with HLA-I molecules. The aim of this study was to analyse the genetic association
between KIR genes and the susceptibility to or protection from
alcoholic cirrhosis (AC) in a cohort of male AC patients undergoing liver
transplantation (LT) with and without concomitant viral infections.
Material and methods: KIR genotyping was performed in nuclear DNA extracted
from 281 AC patients and compared with 319 male controls.
Results: Significant differences between total AC patients and healthy controls
were only found in the case of KIR2DL2 and KIR2DS5. KIR2DL2 was significantly
underrepresented in non-viral AC patients (52.6% vs. 63.3%; p =
0.015), while patients heterozygous for KIR2DL2 were also underrepresented
in the non-viral AC group compared with controls (p = 0.034). KIR2DS5 was
overrepresented in this group compared with healthy controls (p = 0.002). All
these observations were only evident in AC patients older than 54 years old.
Conclusions: Our data suggest a contrary effect of KIR2DL2 and KIR2DS5
in AC patients older than 54 years, in whom the presence of KIR2DL2 appears
to be protective against AC, whereas the presence of KIR2DS5 seems
to promote the fibrotic process, particularly in patients with no associated
viral infection
Remote control of apomorphine infusion rate in Parkinson's disease: Real-time dose variations according to the patients' motor state. A proof of concept.
Determination of selenium levels in dairy products and drinks by hydride generation atomic absorption spectrometry: Correlation with daily dietary intake
Nuclear Magnetic Resonance Metabolomics of Iron Deficiency in Soybean Leaves
Iron (Fe) deficiency is an important agricultural concern that leads to lower yields and crop quality. A better understanding Of the condition at the metabolome level could contribute to the design of strategies to ameliorate Fe-deficiency problems. Fe-sufficient and Fe-deficient soybean leaf extracts and whole leaves were analyzed by liquid H-1 nuclear magnetic resonance (NMR) and high-resolution magic-angle spinning NMR spectroscopy, respectively. Overall, 30 compounds were measurable and identifiable (comprising amino and organic acids, fatty acids, carbohydrates, alcohols, polyphenols, and others), along with 22 additional spin systems (still unassigned). Thus, metabolite differences between treatment conditions could be evaluated for different compound families simultaneously. Statistically relevant metabolite changes upon Fe deficiency included higher levels of alanine, asparagine/aspartate, threonine, valine, GABA, acetate, choline, ethanolamine, hypoxanthine, trigonelline, and polyphenols and lower levels of citrate, malate, ethanol, methanol, chlorogenate, and 3-methyl-2-oxovalerate. The data indicate that the main metabolic impacts of Fe deficiency in soybean include enhanced tricarboxylic acid cycle activity, enhanced activation of oxidative stress protection mechanisms and enhanced amino acid accumulation. Metabolites showing accumulation differences in Fe-starved but visually asymptomatic leaves could serve as biomarkers for early detection of Fe-deficiency stress
Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): An investigator-driven, open-label, randomized, noninferiority controlled trial
Background: Colistin is recommended in the empirical treatment of ventilator-associated pneumonia (VAP) with a high prevalence of carbapenem-resistant gram-negative bacilli (CR-GNB). However, the efficacy and safety of colistin are not well defined. Methods: A multicenter prospective randomized trial conducted in 32 European centers compared the efficacy and safety of colistin (4.5 million unit loading dose followed by a maintenance dose of 3 million units every 8 h) versus meropenem (2 g every 8 h), both in combination with levofloxacin (500 mg every 12 h) for 7-14 days in patients with late VAP. Between May 2012 and October 2015, 232 patients were randomly assigned to the 2 treatment groups. The primary endpoint was mortality at 28 days after randomization in the microbiologically modified intention-to-treat (mMITT) population. Secondary outcomes included clinical and microbiological cure, renal function at the end of the treatment, and serious adverse events. The study was interrupted after the interim analysis due to excessive nephrotoxicity in the colistin group; therefore, the sample size was not achieved. Results: A total of 157 (67.7%) patients were included in the mMITT population, 36 of whom (22.9%) had VAP caused by CR-GNB. In the mMITT population, no significant difference in mortality between the colistin group (19/82, 23.2%) and the meropenem group (19/75, 25.3%) was observed, with a risk difference of - 2.16 (- 15.59 to 11.26, p = 0.377); the noninferiority of colistin was not demonstrated due to early termination and limited number of patients infected by carbapenem-resistant pathogens. Colistin plus levofloxacin increased the incidence of renal failure (40/120, 33.3%, versus 21/112, 18.8%; p = 0.012) and renal replacement therapy (11/120, 9.1%, versus 2/112, 1.8%; p = 0.015). Conclusions: This study did not demonstrate the noninferiority of colistin compared with meropenem, both combined with levofloxacin, in terms of efficacy in the empirical treatment of late VAP but demonstrated the greater nephrotoxicity of colistin. These findings do not support the empirical use of colistin for the treatment of late VAP due to early termination. Trial registration: ClinicalTrials.gov, NCT01292031. Registered 9 February 2011. © 2019 The Author(s)